Meet Kimberly Koenig, M.D.
Kimberly Higginbotham Koenig, M.D.
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2002 | The University of Texas Medical School, Houston, Texas, US, MD |
| 1998 | Trinity University, San Antonio, Texas, US, Biology, BS |
Postgraduate Training
| 2005-2008 | Clinical Fellowship, Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2002-2005 | Clinical Residency, Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee |
Licenses & Certifications
| 2024 | Mississippi State Board of Medical Licensure |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Georgia Composite Medical Board |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2023 | Alabama Board of Medical Examiners |
| 2021 | Florida Board of Medicine |
| 2008 | Medical Oncology, Board Certified |
| 2005 | American Board of Internal Medicine |
| 2005 | Texas Medical License |
Experience & Service
Faculty Academic Appointments
Associate Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Assistant Professor, Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2008 - 2015
Medical Oncology Fellow, Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2005 - 2008
Clinical Specialist, Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2005 - 2008
Administrative Appointments/Responsibilities
Director of Clinical Operations, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2021
Associate Director, Nellie B. Connally Breast Center, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Department Quality Officer, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2021
Extramural Institutional Committee Activities
Chair, Chair of Ambulatory Informatic committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Patient Care Informatic Committee (formally Informatic Governance Committee), The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Oncology History Advisory Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Epic Physician Builder, Certified Epic Physician Builder, The University of Texas MD Anderson Cancer Center, 2015 - 2018
Member, Provider Ambassador Network Progam Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2015
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2009 - 2011
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2011
Honors & Awards
| 2019 - 2024 | Certificate of Appreciation, The University of Texas MD Anderson Cancer Center |
| 2007 - 2008 | Elsa U. Pardee Foundation Award, Elsa U. Pardee Foundation |
| 2005 | Golden Fox Award |
| 2005 | The Apple Award |
| 2002 | G. Alan Robinson Award for Pharmacology |
| 2002 | Janet M. Glasgow Achievement Citation, The American Medical Women's Association |
| 2002 | Outstanding Student in Physical Diagnosis, University of Texas |
| 2002 | Outstanding Student in Psychiatry and Behavioral Sciences, University of Texas |
| 2002 | The Eugene D. Jacobsen Award for Integrative Biology |
| 2001 - 2024 | Alpha Omega Alpha Medical Honor Society |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2011. Effect of occult metastases on survival in node-negative breast cancer. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
- 2009. Systemic therapy in elderly breast cancer patients. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2012. Update on the Annual Breast Cancer Symposium. Conference. University of Toledo. Port Arthur, TX, US.
Selected Publications
Peer-Reviewed Articles
- Yam C, Patel M, Hill HA, Sun R, Jr BR, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-34, 2024. e-Pub 2024. PMID: 39356138.
- Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health 19(4):267-273, 2023. e-Pub 2023. PMID: 37795002.
- Abuhadra N, Sun R, Jr BR, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
- Yao S, Janku F, Koenig K, Tsimberidou AM, Piha-Paul SA, Shi N, Stewart J, Johnston A, Bomalaski J, Meric-Bernstam F, Fu S. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med 11(2):340-7, 2022. e-Pub 2022. PMID: 34841717.
- Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
- Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res 27(5):1247-1255, 2021. e-Pub 2021. PMID: 33115815.
- Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(2):e230-e240, 2021. e-Pub 2021. PMID: 33140515.
- Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
- Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2017. PMID: 27893038.
- Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer 8(11):2004-2009, 2017. e-Pub 2017. PMID: 28819400.
- Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S, Research Consortium TBC. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res 22(23):5706-5712, 2016. e-Pub 2016. PMID: 27166393.
- Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
- Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio L, Schlom J, Gulley JL. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 1(8):1087-95, 2015. e-Pub 2015. PMID: 26291768.
- Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer 15(5):325-31, 2015. e-Pub 2015. PMID: 25913905.
- Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol 26(7):1346-52, 2015. e-Pub 2015. PMID: 25878190.
- Agarwal R, Koenig K, Rohren E, Subbiah V. Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation. J Breast Cancer 17(3):287-90, 2014. e-Pub 2014. PMID: 25320628.
- Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 2014. e-Pub 2014. PMID: 24677057.
- Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompsom S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
- Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
- Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Annals Onc doi: 10.1093/annonc/mdu053, 2014. e-Pub 2014.
- Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 2013. e-Pub 2013. PMID: 23053261.
- Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729-734, 2012. e-Pub 2012. PMID: 22291085.
- Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol 29(19):e572-5, 2011. e-Pub 2011. PMID: 21482991.
- Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 134(12):1325-1335, 2008. e-Pub 2008. PMID: 18504614.
Abstracts
- Kaushik J, Koenig K, Michaud M. “Primary Growth Factor Prophylaxis in Breast Cancer Patients Receiving TCHP. HOPA 2019 Annual Conference, 2019. e-Pub 2019.
- Alvarez RH, Chavez-MacGregor M, Ensor J, Murray LJ, Koenig K, Krishnamurthy S, Lucci A, Babiera GV, Woodward W, Whitman GJ, Jackson SA, Shi M, Culver K, Reuben JM, Ueno N, Valero V. A phase II study of dovitinib as salvage therapy in patients with stage IV inflammatory breast cancer HER2-negative with local or distant relapse, 2014. e-Pub 2014.
- Alvarez RH, Ibrahim NK, Ensor J, Koenig K, Chavez-MacGregor M, Gonzalez-Angulo AM, Schwartz Gomez J, Madrigal AG, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Murray LJ, Booser DJ, Cox D, Reuben JM, Valero V. A randomized phase II neoadjuvant study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients with operable breast cancer not overexpressing HER-2, 2014. e-Pub 2014.
- Murthy RK, Varma A, Mishra P, Hess KR, Young EJ, Murray JL, Koenig KH, Greeen MC, Moulder SL, Melhem-Bertrandt A, Booser DJ, Valero V, Hortobagyi GN, Esteva FJ. Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. J Clin Oncol 30(15S):13s, 2012. e-Pub 2012.
- Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Symmans WF, Hortobagyi GN, Crow JR, Shah RR, Hunt KK. Estrogen receptor positivity: 10% or 1%?. Cancer Res 72(24 Suppl):180s, 2012. e-Pub 2012.
- Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Estefa FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% - 10% ER-positive by immunohistochemistry. Cancer Res 71(Suppl 24):191s, 2011. e-Pub 2011.
Patient Reviews
CV information above last modified July 22, 2026